Evidence map›Paper›PMID 26248203›Full record

ArticleAntiviral research2015

Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.

Yu-Na Lee, Min-Chul Kim, Young-Tae Lee, Yu-Jin Kim, Jongsang Lee, Cheol Kim, Suk-Hoon Ha, Sang-Moo Kang

Abstract read
In one paragraph

Article in Antiviral research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 2 countries.

Yu-Na LeeCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Min-Chul KimCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA; Animal and Plant Quarantine Agency, 175 Anyangro, Anyang, Gyeonggi-do 430-757, Republic of Korea.
Young-Tae LeeCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Yu-Jin KimCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.
Jongsang LeeBEAMS Biotechnology Co. Ltd., Seongnam, Gyeonggi-do, Republic of Korea.
Cheol KimBEAMS Biotechnology Co. Ltd., Seongnam, Gyeonggi-do, Republic of Korea.
Suk-Hoon HaMogam Biotechnology Research Institute, Yongin, Gyeonggi-do, Republic of Korea.
Sang-Moo KangCenter for Inflammation, Immunity & Infection, Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA. Electronic address: skang24@gsu.edu.
Georgia State University · US

Funding

Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
VLP Vaccine TechnologyR01AI105170 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2013 to 2017
$3.7M
LAIV Inducing Cross ProtectionR21AI119366 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2015 to 2016
$415k
NIAID NIH HHS AI093772NIAID NIH HHS AI105170NIAID NIH HHS AI119366NIAID NIH HHS R01 AI093772NIAID NIH HHS R01 AI105170NIAID NIH HHS R21 AI119366
6 · The paper itself

Abstract

Current influenza vaccines are less efficacious against antigenically different influenza A viruses. This study presents an approach to overcome strain-specific protection, using a strategy of co-immunization with seasonal H3N2 split vaccine and yeast-expressed soluble proteins of a tandem repeat containing heterologous influenza M2 ectodomains (M2e5x). Co-immunization with both vaccines in mice was superior to either vaccine alone in inducing cross protection against heterologous H3N2 virus by raising M2e-specific humoral and cellular immune responses toward a T-helper type 1 profile inducing IgG2a isotype antibodies as well as interferon-γ-producing cells in systemic and mucosal sites. In addition, co-immunization sera were found to confer cross-protection against different subtypes of H1N1 and H5N1 influenza A viruses in naïve mice. A mechanistic study provides evidence that activation of dendritic cells by co-stimulation with M2e5x and split vaccine was associated with the proliferation of CD4(+) T cells. Our results suggest that a strategy of co-immunization with seasonal split and M2e5x protein vaccines could be a promising approach for overcoming the limitation of strain-specific protection by current influenza vaccination.

Indexed as

VaccinationAnimalsAntibodies, ViralCD4-Positive T-LymphocytesCross ProtectionHumansImmune SeraImmunity, CellularImmunity, HumoralImmunoglobulin GInfluenza A virusInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza A Virus, H5N1 SubtypeInfluenza, HumanInfluenza VaccinesAntibodies, ViralImmune SeraImmunoglobulin GInfluenza VaccinesInterferon-gammaM2 protein, Influenza A virusViral Matrix ProteinsViroporin ProteinsAS04Influenza virusM2e5xProteinSplit vaccine

Identifiers

PMID26248203
PMCPMC4560976
OpenAlexW2237606379

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.